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The clinical dynamics of influenza A(H1N1) 2009 infections in 61
laboratory-confirmed Dutch cases were examined. An episode
lasted a median of 7Æ5 days of which 2 days included fever.
Respiratory symptoms resolved slowly, while systemic symptoms
peaked early in the episode and disappeared quickly. Severity of
each symptom was rated highest in the first few days.
Furthermore, diarrhoea was negatively associated with viral load,
but not with faecal excretion of influenza virus. Cases with
comorbidities appeared to have higher viral loads than the cases
without, suggesting a less effective immune response. These results
complement information obtained through traditional
surveillance.
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Introduction
In 2009, a novel influenza A(H1N1) virus caused the first
influenza pandemic of the 21st century.1,2 In the Nether-
lands, the first case of infection with the pandemic virus
strain was reported on 30 April, and 1622 cases were regis-
tered until 15 August 2009.3 On this date, the notification
criteria were narrowed to hospitalized and deceased labora-
tory-confirmed cases only.4 Little is known about the clini-
cal dynamics of symptoms during an influenza infection,
despite this information being of potential use for control
efforts, policy and communication. We investigated the
dynamics of symptoms of pandemic influenza
A(H1N1)pdm09 infections in community cases in the
Netherlands, and studied possible relationships between
symptoms and viral load.
Methods
A core research protocol was designed to enable collection
of relevant data in case of an epidemic of an unusual
human influenza virus. This protocol and the adapted 2009
version were approved by the Medical Ethical Review Com-
mittee of the University Medical Centre, Utrecht.
Laboratory-confirmed cases were recruited via municipal
health services, general practitioners and academic hospitals.
Between 30 April and 14 August 2009, cases could be drawn
from notification data. As from 15 August, recruitment was
continued in collaboration with the Sentinel General
Practice Network of NIVEL, the Netherlands Institute for
Health Services Research.5 Twelve of the 42 GP practices
were willing to participate requiring the GP to collect a nose
and throat swab and finger prick sample at time of consul-
tation. These samples had to be taken within 4 days of onset
of illness. In November and December 2009, patients with a
laboratory-confirmed infection hospitalized in one of three
university hospitals were also approached.
Consenting patients agreed to sequential sampling of
nose-throat swabs and blood specimens (Table 1). Further-
more, cases completed a questionnaire about demograph-
ics, medical history, vaccinations, symptoms and the use of
antivirals. The cases were also asked to keep a daily diary
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recording symptoms and the use of antivirals each day for
a maximum of 14 days. The cases rated severity of each
symptom on a scale ranging from 0 (none experienced) to
10 (symptom was present throughout the day) by the case.
Real-time RT-PCR for detection of A(H1N1)pdm09
virus in combined nose and throat swabs and in rectal
swabs was performed as described previously.6 To deter-
mine of the exact viral load in virus particles per ml, an
electron microscopy (EM)-counted standard of human
influenza virus A ⁄PuertoRico ⁄ 8 ⁄ 1934 (H1N1) was used
(provided by M. Schutten, Erasmus MC, Rotterdam, NL).
All clinical specimens and a dilution series of the
EM-counted control were retrospectively subjected batch-
wise to RNA isolation and one-step matrix gene-based
real-time RT-PCR, and the viral loads of the clinical speci-
mens were estimated based on the batch calibration curve.
The evolution of symptoms was examined by calculating
the percentage of cases experiencing each symptom per
day, together with the median severity score per symptom
per day. The diary could be completed for a maximum of
14 days, which led to a censoring of duration of illness for
cases who had symptoms for a longer period. Associations
between the highest estimated viral load in the first 5 days
of illness and age, gender, underlying disease, duration of
illness, and reported symptoms on the day of sampling
were examined using the Kruskal–Wallis test or Spearman
correlation. Secondly, associations between all estimated
viral loads and severity scores per symptom on the day of
sampling were calculated using Spearman correlations. All
analyses were carried out for all cases, stratifying by the use
of antivirals.
Results
A total of 120 laboratory-confirmed cases were approached;
76 (63%) were willing to participate of whom 61 (51%)
cases reported their symptoms either in the questionnaire
(46 cases) and ⁄or in the diary (38 cases). Table 2 shows
the characteristics of the cases. Forty-three per cent of the
cases had one or more underlying diseases. Thirty-four
cases were treated with oseltamivir, and about two-thirds
started treatment within 3 days of the first symptoms
occurring (range 1–7 days). The cases reported an overall
median duration of illness of 7Æ5 days (range 2–21 days).
The admitted cases were hospitalized for 3–9 days, and had
a median duration of illness of 10 days (range 7–13 days).
Cases with fever reported a maximum of 6 days of fever
with a median of 2 days (Figure 1). Other symptoms lasted
longer. Complaints of coughing were still present in more
than 10% of the cases at day 14. Men appeared to have
fever for a longer period (4 days; 1–6 days) than women
[1Æ5 days; 1–5 days (P = 0Æ09)].
All cases coughed in the first few days of illness and
these complaints persisted (Figure 2). Dyspnoea (data not
shown) followed a comparable pattern as rhinorrhoea.
Myalgia peaked at day 2–4 (71–75% of the cases). Diar-
rhoea was reported most frequently between day 4 and 6
(almost half of the cases). Nausea was reported by one-
third of the cases on day 1, and then declined. The severity
of complaints was highest in the first 4 days for all symp-
toms (Figure 3). A notable result is the unexplained rise in
score for sputum production after day 9.
Table 1. Research scheme of sampling and questionnaires per
house visit
Visit 1* =
Day 0
Visit 2* =
Day 4–6
Visit 3 =
Day 9–11
Visit 4 =
Day 28–35
Informed consent X
Swabs
Throat ⁄ nose X X
Rectal X
Venous blood X X X
Questionnaire X
Symptoms diary X X X X
*For cases recruited through the GP, visit 1 and 2 were combined.
Table 2. Characteristics of cases with a laboratory-confirmed
influenza A(H1N1) 2009 virus infection (n = 61)
n (%)
30 April–14 August 2009
Via municipal health services 36 (59)
15 August–31 December 2009
Via GPs 19 (31)
Via academic centres 6 (10)
Age, in years
4–18 16 (26)
20–39 26 (43)
40–59 12 (20)
60–69 7 (11)
Gender
Male 26 (43)
Female 35 (57)
Underlying disease
No severe or chronic disease 20 (33)
Severe or chronic disease 26 (43)
Lung disease 13 (21)
Other disease 7 (11)
More than one disease 6 (10)
Unknown 15 (25)
Antiviral medication
Yes 36 (59)
No 23 (38)
Unknown 2 (3)
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Ninety-two per cent of the nose-throat swabs taken
within 1 week after onset of illness were positive (46 ⁄ 50)
compared to 24% (9 ⁄ 37) in the second and 18% (4 ⁄ 22) in
the third week. Two samples from one case were still posi-
tive at day 24 and 39. Five of the six positive samples taken
more than 14 days after day of onset were from three
hospitalized cases. Four cases, with a period of illness of
3–12 days, had a positive swab (<3000 viral particles ⁄ml)
at 1–3 days after clinical recovery.
Viral load data were available for 73 samples of 42 cases.
Median load was 8130 viral particles ⁄ml (range:
20–117 000 000). No difference in load was seen between
samples taken at day 1–2 versus day 3–5 post onset of ill-
ness or use of antivirals. Cases with underlying disease had
a higher viral load than the cases without. No difference in
prescription of antivirals was seen between cases with and
without underlying disease. A negative correlation was
found between number of days with diarrhoea and highest
available viral load [)0Æ39 (P = 0Æ02)], but no association
between viral load and severity score for diarrhoea on the
day of sampling was seen.
A rectal swab, taken between day 4 and day 13, was
available for 31 cases. Four specimens were positive, two
cases had diarrhoea somewhere during their episode of
influenza, but none on the day of sampling. Of the 27 cases
with a negative rectal sample, 13 had reported at least
1 day of diarrhoea.
Discussion
Cases with comorbidities had on average a higher viral load
than cases without, but without difference in the duration
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Figure 1. Duration of clinical symptoms, showing median, 90-percentile and 95-percentile per symptom.
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Figure 2. Percentage of cases reporting the experience of each symptom per day.
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of illness. The opposite has been reported for seasonal
influenza, but no association was found for
A(H1N1)pdm09 influenza.7 Previous comparisons of cases
of varying severity did not reveal differences in initial viral
loads, but patients with more severe disease or with comor-
bidities cleared the virus more slowly.8,9 A negative associa-
tion was only found between viral load and diarrhoea in
the present study, whereas Li et al10 found higher viral
loads in patients with fever and in patients who developed
pneumonia. Faecal excretion of A(H1N1)pdm09 influenza
virus could not be linked to diarrhoea in the current study,
which has also been reported elsewhere.11
Initially, the course of the 2009 pandemic resulted in
staff resource challenges, which made it difficult to include
more cases. Subsequently, the mandatory notification in
the Netherlands was restricted, and a new route for inclu-
sions had to be found. The relatively low numbers reduce
the power of the study. Seventy per cent of the participants
reported underlying diseases, mainly lung diseases (39%),
compared to 16Æ8% of all notified laboratory-confirmed
cases in the Netherlands (9Æ1% lung diseases),3 indicating
that selection bias is likely to have occurred. Cases with
comorbidities may be more prone to participate. Further-
more, people with comorbidities will visit their GP faster
in the case of influenza-like illness (ILI) than healthy per-
sons experiencing ILI, and thus have a higher chance to be
included. However, no indications were found for a differ-
ent course of the disease in the cases with comorbidities.
In conclusion, the pandemic offered a unique opportu-
nity to investigate the clinical dynamics of influenza, com-
plementing the information obtained through traditional
public health surveillance. Systemic symptoms dominated
during the first 4 days, whereas respiratory symptoms
peaked in the first few days and resolved slowly. The sever-
ity of each symptom was rated highest in the first few days
and then declined. Diarrhoea appeared to be negatively
associated with viral load, but not with faecal excretion of
influenza virus. Patients with underlying disease seemed to
have higher viral loads, suggesting a less effective immune
response, although they were not significantly more
severely ill.
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Figure 3. Median severity score (1–10) per day per symptom as reported by the cases (when reported by at least six cases per day).
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